Anticoagulants in adult extracorporeal membrane oxygenation: alternatives to standardized anticoagulation with unfractionated heparin

Eur J Clin Pharmacol. 2023 Dec;79(12):1583-1594. doi: 10.1007/s00228-023-03568-3. Epub 2023 Sep 23.

Abstract

Background: Extracorporeal membrane oxygenation (ECMO) is a vital technique for severe respiratory or heart failure patients. Bleeding and thrombotic events are common during ECMO and negatively impact patient outcomes. Unfractionated heparin is the primary anticoagulant, but its adverse effects limit its use, necessitating alternative anticoagulants.

Objective: Review available alternative anticoagulants for adult ECMO patients. Explore potential novel anticoagulants for future ECMO use. Aim to reduce complications (bleeding and thrombosis) and improve safety and efficacy for critically ill ECMO patients.

Methods: Comprehensive literature review of existing and emerging anticoagulants for ECMO.

Results: Identified a range of alternative anticoagulants beyond unfractionated heparin. Evaluated their potential utility in mitigating ECMO-related complications.

Conclusion: Diverse anticoagulant options are available and under investigation for ECMO. These alternatives may enhance patient safety and outcomes during ECMO support. Further research and clinical studies are warranted to determine their effectiveness and safety profiles.

Keywords: Alternative anticoagulants; Bleeding and thrombotic events; Coagulation factors; Contact system; ECMO; UFH.

Publication types

  • Review

MeSH terms

  • Adult
  • Anticoagulants / adverse effects
  • Blood Coagulation
  • Extracorporeal Membrane Oxygenation*
  • Hemorrhage / chemically induced
  • Heparin / adverse effects
  • Humans
  • Retrospective Studies
  • Thrombosis* / etiology

Substances

  • Heparin
  • Anticoagulants